Literature DB >> 32959937

SP1-induced lncRNA FOXD3-AS1 contributes to tumorigenesis of cervical cancer by modulating the miR-296-5p/HMGA1 pathway.

Wen-Guang Ma1, Si-Mao Shi1, Lu Chen1, Ge Lou2, Xiao-Ling Feng1.   

Abstract

Long noncoding RNAs (lncRNAs) have drawn growing attention due to their regulatory roles in various diseases, including tumors. Recently, lncRNA FOXD3 antisense RNA 1 (FOXD3-AS1) was shown to be overexpressed in colon adenocarcinoma and glioma, exerting oncogenic functions. However, its expression and effects in cervical cancer (CC) remained unknown. In this research, our group first reported that the levels of FOXD3-AS1 were distinctly elevated in CC samples and cell lines. The distinct upregulation of FOXD3-AS1 was associated with lymphatic invasion, distant metastasis, and International Federation of Gynecology and Obstetrics stage, and also predicted poor clinical results of CC patients. Next, transcription factor SP1 was demonstrated to resulting in the upregulation of FOXD3-AS1 in CC. Functional assays indicated that knockdown of FOXD3-AS1 distinctly suppressed CC progression via affecting cell proliferation, cell apoptosis, and metastasis. Moreover, mechanistic studies suggested that FOXD3-AS1 acted as an endogenous sponge by directly binding miR-296-5p, resulting in the suppression of miR-296-5p. In addition, we also reported that high mobility group A, a direct target of miR-296-5p, could mediate the tumor-promotive effects that FOXD3-AS1 displayed. Overall, our present study might help to lead a better understanding of the pathogenesis of CC, provide a novel possible tumor biomarker, and probe the feasibility of lncRNA-directed treatments for CC.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  HMGA1; biomarker; cervical cancer; lncRNA FOXD3-AS1; metastasis; miR-296-5p

Year:  2020        PMID: 32959937     DOI: 10.1002/jcb.29846

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.

Authors:  Gege Shu; Huizhao Su; Zhiqian Wang; Shihui Lai; Yan Wang; Xiaomeng Liu; Luo Dai; Yin Bi; Wei Chen; Weiyu Huang; Ziyan Zhou; Songqing He; Hongliang Dai; Bo Tang
Journal:  J Exp Clin Cancer Res       Date:  2021-01-26

Review 2.  An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma.

Authors:  Francesca Baldini; Matilde Calderoni; Laura Vergani; Paola Modesto; Tullio Florio; Aldo Pagano
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

3.  LncRNA FOXD3-AS1 Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/SZRD1 Axis.

Authors:  Zhang Li; Ming Li; Pengcheng Xia; Lili Wang; Zhiming Lu
Journal:  Cancer Manag Res       Date:  2021-12-07       Impact factor: 3.989

Review 4.  Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases.

Authors:  Qinfan Yao; Xiuyuan Zhang; Dajin Chen
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

5.  Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis.

Authors:  Jun Liu; Yingmei Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.

Authors:  Xiaofeng Liu; Wenyan Chen; Yu Qi; Yongqian Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-14       Impact factor: 2.650

7.  Circular RNA hsa_circ_0000511 Improves Epithelial Mesenchymal Transition of Cervical Cancer by Regulating hsa-mir-296-5p/HMGA1.

Authors:  Jia Xie; Qian Chen; Ping Zhou; Wenli Fan
Journal:  J Immunol Res       Date:  2021-05-27       Impact factor: 4.818

8.  The Value of miR-296 and miR-517c in Evaluating the Prognosis of Patients with Glioma after Radiotherapy and Chemotherapy.

Authors:  Weiyu Wang; Aigang Shi; Bing Lei; Kaichuang Yang; Weihua Zhang; Peng An
Journal:  J Oncol       Date:  2021-12-16       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.